2 assets in Central Neurocytoma

Therapeutic assets addressing Central Neurocytoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dabrafenib Central Neurocytoma	Novartis Pharmaceuticals	P4	BB (65)
Trametinib Central Neurocytoma	Novartis Pharmaceuticals	P4	BB (65)